• Alias: HuMax-EGFR
    • A fully human IgG1 monoclonal antibody that selectively binds to the EGFR receptor and blocks the receptor binding of EGF and TGF-α
    • Designed for the treatment of SCCHN
    • Completed phase 3 study shows an increase in PFS.
    • Recommended dose: A loading dose of 8 mg/kg followed by two weekly doses of 4 mg/kg by IV infusion over 60 minutes
    • Half-life: Increased with dose from 5 hours for 0.15 mg/kg to 66 hours for 8.0 mg/kg dose
    • Common side effects: Rash, anemia, pyrexia, headache, and skin and nail disorder
    Other topics in Targeted and Immunotherapy Agents